Literature DB >> 32949596

Glucagon-like peptide-1 cleavage product GLP-1(9-36) reduces neuroinflammation from stroke via the activation of insulin-like growth factor 1 receptor in astrocytes.

Jing Huang1, Yunhan Liu2, Liusiyuan Cheng3, Jihong Li3, Tangrui Zhang3, Gang Zhao4, Huinan Zhang5.   

Abstract

Glucagon-like peptide-1 (GLP-1) is an endogenous gut hormone and a key regulator in maintaining glucose homeostasis by stimulating insulin secretion. Its natural cleavage product GLP-1 (9-36), which was formerly considered a "bio-inactive" metabolite mainly due to its low affinity for GLP-1 receptor, possesses unique properties such as cardiovascular protection. Little is known about the effects and mechanisms of GLP-1 (9-36) in cerebral ischemia and reperfusion injury. Here, we report that systemic application of GLP-1 (9-36) in adult mice facilitated functional recovery and reduced infarct volume, astrogliosis, and neuronal apoptosis following middle cerebral artery occlusion and reperfusion. Interestingly, these effects were still observed in GLP-1 receptor knockout (Glp-1rKO) mice but were partially reversed in insulin-like growth factor 1 (IGF-1) receptor knockdown (Igf-1rKD) mice. Primary astrocytes were cultured and subjected to oxygen-glucose deprivation/reoxygenation (OGD/R), and enzyme-linked immunosorbent assay indicated that GLP-1 (9-36) pretreatment reduces tumor necrosis factor-α, interleukin (IL)-1β, and IL-6 levels. This effect was not diminished in Glp-1rKO astrocytes but was reversed in Igf-1rKO astrocytes, emphasizing that the anti-inflammatory effect of GLP-1 (9-36) in astrocytes is independent of GLP-1 receptor signaling and is instead mediated by IGF-1 receptor. Immunoprecipitation experiments showed that GLP-1 (9-36) directly interacts with IGF-1 receptor in astrocytes. Western blot data indicated that GLP-1 (9-36) activates IGF-1 receptor and downstream PI3K-AKT pathway in astrocytes upon OGD/R injury, which was abrogated by preincubation with IGF-1 receptor autophosphorylation inhibitor picropodophyllin. Thus, our findings suggest that GLP-1 (9-36) improved stroke outcome by reducing inflammation in astrocytes via interaction with IGF-1 receptor.
Copyright © 2020. Published by Elsevier B.V.

Entities:  

Keywords:  Astrocytes; GLP-1(9–36); Insulin-like growth factor 1 receptor; Neuroinflammation; Stroke

Mesh:

Substances:

Year:  2020        PMID: 32949596     DOI: 10.1016/j.ejphar.2020.173581

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  7 in total

1.  Sleeve Gastrectomy Improves High-Fat Diet-Associated Hepatic Steatosis Independent of the Glucagon-like-Petpide-1 Receptor in Rats.

Authors:  Matthew Barron; Hailey Hayes; Deemantha G Fernando; Aron M Geurts; Tammy L Kindel
Journal:  J Gastrointest Surg       Date:  2022-05-26       Impact factor: 3.267

2.  Preclinical and clinical evidence of IGF-1 as a prognostic marker and acute intervention with ischemic stroke.

Authors:  Cellas A Hayes; M Noa Valcarcel-Ares; Nicole M Ashpole
Journal:  J Cereb Blood Flow Metab       Date:  2021-03-24       Impact factor: 6.200

3.  The metabolite GLP-1 (9-36) is neuroprotective and anti-inflammatory in cellular models of neurodegeneration.

Authors:  Yazhou Li; Elliot J Glotfelty; Tobias Karlsson; Lowella V Fortuno; Brandon K Harvey; Nigel H Greig
Journal:  J Neurochem       Date:  2021-10-21       Impact factor: 5.546

Review 4.  GLP-1 Receptor Agonists: Beyond Their Pancreatic Effects.

Authors:  Xin Zhao; Minghe Wang; Zhitong Wen; Zhihong Lu; Lijuan Cui; Chao Fu; Huan Xue; Yunfeng Liu; Yi Zhang
Journal:  Front Endocrinol (Lausanne)       Date:  2021-08-23       Impact factor: 5.555

Review 5.  Mini Review: Effect of GLP-1 Receptor Agonists and SGLT-2 Inhibitors on the Growth Hormone/IGF Axis.

Authors:  Angelo Cignarelli; Valentina Annamaria Genchi; Giulia Le Grazie; Irene Caruso; Nicola Marrano; Giuseppina Biondi; Rossella D'Oria; Gian Pio Sorice; Annalisa Natalicchio; Sebastio Perrini; Luigi Laviola; Francesco Giorgino
Journal:  Front Endocrinol (Lausanne)       Date:  2022-02-21       Impact factor: 5.555

Review 6.  Neuroprotective Mechanisms of Glucagon-Like Peptide-1-Based Therapies in Ischemic Stroke: An Update Based on Preclinical Research.

Authors:  Xiaoyan Yang; Qiang Qiang; Nan Li; Peng Feng; Wenshi Wei; Christian Hölscher
Journal:  Front Neurol       Date:  2022-03-15       Impact factor: 4.003

7.  Sleep duration of lactating mothers and its relationship with feeding pattern, milk macronutrients and related serum factors: A combined longitudinal cohort and cross-sectional study.

Authors:  Huijuan Ruan; Yajie Zhang; Qingya Tang; Xuan Zhao; Xuelin Zhao; Yi Xiang; Wei Geng; Yi Feng; Wei Cai
Journal:  Front Nutr       Date:  2022-08-30
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.